KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell
lung cancer (NSCLC) in Western countries. Of the various KRAS mutants, KRAS G12C is the …

Background Lung cancer is the most common cause of cancer-related mortality in humans.
There are several reasons for this high rate of mortality, including metastasis to several …

Background The brain is a frequent site of metastases from non-small-cell lung cancer
(NSCLC). We analyzed the frequency of brain metastases (BMs) from NSCLC in the era of …

Lung cancer is characterized by the highest incidence of solid tumor-related brain
metastases, which are reported with a growing incidence during the last decade. Prognostic …

Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …

Background Treatment options for oncological diseases have been enhanced by the advent
of targeted therapies. The point mutation of the BRAF gene at codon 600 (BRAF V600E) is …

Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately
one-third of patients with NSCLC have a KRAS mutation. KRAS G12C, the most common …

Objective KRAS mutation plays a critical role in the initiation and development of non‐small
cell lung cancer (NSCLC). KRAS‐mutant patients exhibit diverse response to chemotherapy …

Lung cancer (LC) is the leading cause of cancer mortality worldwide. Despite advances in
the treatment strategy, including surgery, chemotherapy, radiotherapy, immunotherapy, and …

The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class
of drugs for an old target—a narrative review - PMC Back to Top Skip to main content NIH NLM …